Evolus, Inc. (NASDAQ:EOLS - Free Report) - Analysts at HC Wainwright boosted their FY2029 earnings per share estimates for shares of Evolus in a research report issued to clients and investors on Thursday, November 5th. HC Wainwright analyst D. Tsao now expects that the company will earn $1.02 per share for the year, up from their prior estimate of $0.99. HC Wainwright currently has a "Buy" rating and a $13.00 price objective on the stock. The consensus estimate for Evolus' current full-year earnings is ($0.33) per share. HC Wainwright also issued estimates for Evolus' FY2030 earnings at $1.36 EPS.
Other equities research analysts have also recently issued reports about the stock. Wall Street Zen upgraded shares of Evolus from a "hold" rating to a "buy" rating in a report on Saturday, August 8th. BTIG Research lifted their price target on shares of Evolus from $13.00 to $15.00 and gave the company a "buy" rating in a research note on Thursday, November 5th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Evolus in a report on Friday, September 11th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Evolus currently has a consensus rating of "Moderate Buy" and an average target price of $15.00.
Get Our Latest Report on Evolus
Evolus Price Performance
NASDAQ:EOLS opened at $6.96 on Monday. Evolus has a twelve month low of $3.86 and a twelve month high of $9.31. The company has a fifty day moving average of $7.62 and a 200-day moving average of $6.36. The firm has a market capitalization of $460.68 million, a P/E ratio of -14.81 and a beta of 1.38.
Insider Buying and Selling
In other Evolus news, insider David Moatazedi sold 105,108 shares of the firm's stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $9.04, for a total value of $950,176.32. Following the completion of the sale, the insider owned 499,592 shares of the company's stock, valued at approximately $4,516,311.68. This trade represents a 17.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 5.00% of the company's stock.
Institutional Trading of Evolus
Several hedge funds have recently bought and sold shares of EOLS. Nantahala Capital Management LLC raised its holdings in Evolus by 11.5% during the third quarter. Nantahala Capital Management LLC now owns 6,244,690 shares of the company's stock worth $49,958,000 after buying an additional 642,669 shares during the last quarter. BlackRock Inc. bought a new position in shares of Evolus in the second quarter valued at $33,595,000. Braidwell LP grew its holdings in shares of Evolus by 1.6% during the second quarter. Braidwell LP now owns 3,155,209 shares of the company's stock valued at $21,897,000 after buying an additional 50,000 shares during the last quarter. Pinnacle Associates Ltd. grew its holdings in shares of Evolus by 5.6% during the third quarter. Pinnacle Associates Ltd. now owns 1,570,061 shares of the company's stock valued at $12,560,000 after buying an additional 82,797 shares during the last quarter. Finally, Rice Hall James & Associates LLC acquired a new position in shares of Evolus during the second quarter valued at about $8,952,000. Institutional investors and hedge funds own 90.69% of the company's stock.
About Evolus
(
Get Free Report)
Evolus, Inc. is a medical aesthetics company focused on developing and commercializing treatments for cosmetic procedures. The company's portfolio includes injectable products used by healthcare professionals to address facial lines and wrinkles and to enhance facial appearance. Its flagship product, Jeuveau (prabotulinumtoxinA-xvfs), is a prescription botulinum toxin treatment for moderate to severe frown lines between the eyebrows in adults. Evolus also markets Evolysse, a line of hyaluronic acid dermal fillers designed for facial aesthetic treatments.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.